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Abstract Elevated lipoprotein(a) (Lp(a)) has emerged as 
an important independent cardiovascular risk factor, and 
causal association has been accepted with adverse outcome 
in atherosclerotic disease. Lipoprotein apheresis (LA) can 
lower low-density lipoprotein (LDL)-cholesterol and Lp(a) 
by 60–70 % and is the final escalating therapeutic option 
in patients with hyperlipoproteinemias (HLP) involving 
LDL or Lp(a) particles. Major therapeutic effect of LA is 
preventing cardiovascular events. Stabilizing plaque mor-
phology might be an important underlying mechanism of 
action. In Germany, since 2008, a reimbursement guideline 
has been implemented to establish the indication for LA 
not only for familial or severe forms of hypercholester-
olemia but also for Lp(a)-HLP associated with a progres-
sive course of cardiovascular disease, that persists despite 
effective treatment of other concomitant cardiovascular 
risk factors, i.e. isolated Lp(a)-HLP. The Pro(a)LiFe-study 
confirmed with a prospective multicenter design that LA 
can effectively reduce Lp(a) plasma levels and prevent car-
diovascular events.
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Lipoprotein-Apherese erreicht Plaque-Stabilisierung 
und Prävention kardiovaskulärer Ereignisse – 
Kommentar zur prospektiven Pro(a)LiFe-Studie
Zusammenfassung Ein erhöhter Spiegel von Lipoprote-
in(a) (Lp(a)) ist ein bedeutender unabhängiger und kausal 
zu wertender kardiovaskulärer Risikofaktor. Die Lipopro-
tein-Apherese (LA) kann LDL-Cholesterin und Lp(a) um 
60–70 % absenken und ist die ultima ratio der Therapie-
Eskalation bei Hypercholesterinämie und Lp(a)-Hyperlipo-
proteinämie (Lp(a)-HLP). Der wesentliche therapeutische 
Effekt der LA besteht in der Prävention kardiovaskulä-
rer Ereignisse. Die Stabilisierung der Plaquemorphologie 
könnte hierbei ein wichtiger Wirkmechanismus sein. Die 
deutschen Erstattungsrichtlinien für die LA umfassen seit 
2008 nicht nur die familäre und schwere Hypercholesterin-
ämie sondern auch die Lp(a)-HLP mit progredienter Gefäß-
erkrankung, die persistiert trotz effektiver Behandlung aller 
bestehenden kardiovaskulären Risikofaktoren und dann als 
isolierte Lp(a)-HLP bezeichnet wird. Die Pro(a)LiFe-Stu-
die bestätigte mit prospektivem Multicenter-Design, daß die 
LA zur effektiven Reduktion der Lp(a)-Spiegel und Präven-
tion kardiovaskulärer Ereignisse führte.
Schlüsselwörter Lipoprotein-Apherese · Lipoprotein(a) · 
Kardiovaskuläre Erkrankung · Plaque Stabilisierung · 
Koronare Herzerkrankung · Prävention
Background
It lasted nearly 50 years after first description in 1963 until 
elevated lipoprotein(a) (Lp(a)) has been accepted as an 
important independent and causal risk factor associated with 
adverse outcome in atherosclerotic disease [1]. Part of the 
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long-term misconceiving of Lp(a) were problems with labora-
tory measurement. In 1993, analysis of the physicians’ health 
study concluded on no evidence of association between Lp(a) 
level and risk of future coronary artery disease [2]. Then it 
became clear that the enzyme-linked immunosorbent assay 
used in the study was susceptible to freezing artifacts [3]. Re-
evaluation of the study revealed that Lp(a) predicted risk of 
coronary artery disease [4]. The physiological role of Lp(a) 
still remains to be fully elucidated. Pathogenic mechanisms 
linked to elevated Lp(a) levels can potentially increase the 
risk of cardiovascular disease (CVD) via prothrombotic or 
antifibrinolytic effects and via accelerated atherogenesis as a 
result of intimal deposition of Lp(a), or both [1].
Lipoprotein apheresis (LA) is the final escalating option 
to lower blood low-density lipoprotein cholesterol (LDL-C) 
levels in severely hypercholesterolemic patients including 
familial hypercholesterolemia, resistant to or intolerant of 
lipid lowering medication. Since 1991, regular reimburse-
ment of LA has been implemented in guidelines of statutory 
health insurance funds in Germany. Ability of LA methods 
to lower Lp(a) as effective as LDL-C led to encouraging 
pilot experiences in a small number of patients with Lp(a)-
hyperlipoproteinemias (HLP) and exceedingly progressive 
CVD in the early 1990s. In 2008, German Federal Joint 
Committee (GBA) decided to accept Lp(a)-HLP as separate 
indication for chronic LA. Lp(a)-HLP must have Lp(a) lev-
els > 60 mg/dl and should be isolated in the sense that all 
other cardiovascular risk factors in particular LDL-C have 
to be under optimized treatment [5]. Lp(a) levels are gener-
ally not influenced by lifestyle. Nicotinic acid at high doses 
has shown Lp(a) lowering but was withdrawn in Europe in 
2013. GBA stipulated with the new reimbursement guide-
line that additional prospective data are required to justify 
its maintenance. A longitudinal cohort study for the first time 
documented the therapeutic potential of LA to prevent car-
diovascular events in this subgroup of CVD patients before 
the current reimbursement guideline was implemented [6]. 
These results strongly supported ethical concerns to with-
hold LA to such high-risk patients in a randomized con-
trolled trial, which consequently could not achieve ethics 
committee approval. The best possible way to generate new 
prospective data in this situation was conduct of a prospec-
tive cohort study comparing the incidence of cardiovascular 
events in patients with Lp(a)-HLP and progressive CVD 
retrospectively before and prospectively after commenc-
ing chronic LA. Two-year results of the 5-year prospective 
Pro(a)LiFe-study have been published [7].
Patients
The German reimbursement guideline permits LA for patients 
with Lp(a) > 60 mg/dl, LDL-C in normal range, and persisting 
progressive CVD in coronary, peripheral, or cerebral vascular 
beds. No further explanations were specified by GBA how to 
define normal range of LDL-C and progression of CVD or 
what other clinical conditions should be exhibited by candi-
dates for LA. Hurdles for approval of chronic LA have been 
set high resulting in very select patients. According to current 
practice, the following conditions carry weight for assessing 
the individual risk profile and approval of LA by committees 
of regional associations of statutory health insurance physi-
cians: progressive CVD as documented clinically and with 
imaging techniques, established maximally tolerated lipid-
lowering drug treatment, recent cardiovascular events despite 
efficient drug treatment, out-of-the-ordinary frequency of 
cardiovascular events, early CVD in the patient, or positive 
family history of early CVD. It should be noted, that from 
the clinical point of view an acute event alone would not ful-
fill requirements of the guideline, on the other hand a recent 
acute event is no prerequisite for approval.
Study design
Design of a prospective observational study was chosen 
for Pro(a)LiFe comparing the incidence of cardiovascular 
events in patients with Lp(a)-HLP and progressive CVD 
with a predefined uniform observation period retrospec-
tively before and prospectively after commencing chronic 
LA. The past 2 years prior to commencing LA were selected 
as the major period of retrospective analysis, as they should 
have the best quality of retrospective data. Additionally, 
time of diagnosis and times of first and second cardiovas-
cular events were documented. The first 5 years after com-
mencing LA were selected for prospective analysis. Results 
of the first cohort study were used as guidance for sample 
size estimation [6, 7].
Threshold of 60 mg/dl for Lp(a) in the German 
reimbursement guideline for LA
Lp(a) is a plasma lipoprotein consisting of a cholesterol-rich 
LDL particle with one molecule of apolipoprotein B100 and 
an additional apolipoprotein(a) (apo(a)) molecule. Apo(a) 
contains ten different types of plasminogen kringle 4-like 
repeats as well as regions homologous to the kringle 5 and 
protease-P of plasminogen. The kringle 4 type 2 domain is 
present in multiple repeated copies that differ in number (2 
to > 40) between apo(a) isoforms [1]. Additionally, choles-
terol, triglyceride, and phospholipid content as well as the 
carbohydrate component of Lp(a) are not constant resulting 
in even more aspects of Lp(a) polymorphism constituting 
a serious challenge for the immunochemical measurement 
of Lp(a) in plasma [1, 8, 9]. Results for Lp(a) levels vary 
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Two-year results of the Pro(a)LiFe study
A total of 170 patients commencing LA due to Lp(a)-HLP 
with Lp(a) > 60 mg/dl and progressive CVD were enrolled 
in the Pro(a)LiFe-study. LA effectively lowered Lp(a) 
plasma levels by 74 % and significantly lowered incidence 
rates of cardiovascular events by 78 % in coronary arter-
ies and by 74 % for all vascular beds in the 2-year blocks 
before and after commencing LA [7, Figs. 1 and 2]. Cor-
recting LDL-C levels for Lp(a)-cholesterol content under-
from method to method depending on how the value to the 
calibrators were assigned and the magnitude of the impact 
of apo(a) size variability to the particular assay. These dif-
ficulties with Lp(a) laboratory measurement do not question 
the clinically relevant pathophysiological role of Lp(a) but 
complicate comparison of scientific study results, reliable 
diagnosis of Lp(a) levels, and individual classification of 
cardiovascular risk.
The Lp(a) threshold of 60 mg/dl had been finally fixed by 
the German federal authority. It must be regarded as arbi-
trary to a certain extent being not fully inferable by scientific 
data. However, it is in use to approve the clinical decision 
for commencing LA. Guidance is provided by the 30 mg/
dl threshold often quoted with increased cardiovascular risk 
and by the European Consensus Panel mentioning a desir-
able level below the 80th percentile in Western populations, 
i.e., < 50 mg/dl [1, 10–12]. Alternatively for Caucasians, 
based on the Framingham data, a Lp(a) value of 75 nmol/l is 
quoted with increased risk for CVD [9]. However, an analy-
sis from the white population in New Zealand set a simi-
lar risk threshold at 45 nmol/l [13]. Risk in male patients 
appears to be higher in almost all studies [12, 14].
Measurement of total Lp(a) mass in mg/dl could only be 
converted into a molar unit, if an accurate molecular weight 
would be available. The problem is that there are too many 
variables that play a role in converting Lp(a) values in mg/dl 
obtained by methods calibrated in terms of total Lp(a) mass 
to Lp(a) values in nmol/l obtained by methods calibrated 
by the World Health Organization/International Federation 
of Clinical Chemistry reference material [9]. There is no 
routine assay for determining kringle 4 type 2 repeat num-
ber in patients. Size of apo(a) is genetically determined and 
inversely but not exactly correlated with plasma levels. Even 
for apo(a) isoforms, published data on molecular weight dif-
fer substantially [15–17]. The same apo(a) allele can have 
different plasma levels [18]. LPA-gene exhibits heterozy-
gosity in > 95 % of patients[19]. Expression of both alleles 
can be detected in 40–75 % of patients with one allele being 
predominantly expressed in most cases [20, 21]. Therefore, 
a general conversion factor from a mass unit into a molar 
unit cannot exist for Lp(a). The factor recommended by the 
American Medical Association Manual of Style, which was 
used in the Pro(a)LiFe publication, should be disregarded 
as erroneous [22]. According to the German reimbursement 
guideline, there is the need to classify patients with a Lp(a) 
mass threshold (i.e., > 60 mg/dl). Ranges and percentiles of 
Lp(a) levels for defined populations using Lp(a) assays stan-
dardized for molar number or mass of Lp(a) particles and 
tested in parallel series would be necessary to define popula-
tion specific estimates of risk thresholds. The 80th percen-
tile of Lp(a) levels could be a good candidate for high-risk 
patients (Marcovina, personal communication, [1]).
Fig. 1 Mean plasma concentrations of lipoprotein(a) (Lp(a)) and LDL-
cholesterol (LDL-C) before and after commencing chronic lipoprotein 
apheresis (LA) (modified according to [7]). Sawtooth-like pattern of 
Lp(a) and LDL-C levels illustrates weekly changes during chronic LA 
with approximately > 60–70 % reduction after a single treatment: a 
Lp(a), b LDL-C, c LDL-C after correction for Lp(a) cholesterol esti-
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warning. Superficial erosion of a coronary artery with rupture 
of the plaque’s fibrous cap is thought to cause the majority of 
these severe acute complications [23]. A fibrous cap typically 
overlies a lipid-rich center also known as the necrotic core. 
Pathogenic mechanisms promoting atherosclerosis linked to 
elevated Lp(a) include Lp(a)-derived cholesterol entrapment 
in the intima, via inflammatory cell recruitment and/or via the 
binding of pro-inflammatory-oxidized phospholipids. Ele-
vated Lp(a) is prothrombotic via the inhibition of fibrinolysis 
with enhancement of clot stabilization as well as via enhanced 
coagulation via the inhibition of tissue factor pathway inhibi-
tor [1]. Ruptured plaques tend to have large lipid cores and 
abundant inflammatory cells. At the tissue level, improving 
plaque morphology could be one underlying mechanism of 
action for preventing clinical events by LA: quantitatively by 
reducing the number of vulnerable plaques and qualitatively 
by limiting the propensity of plaques to rupture and their 
thrombogenicity rather than quantitative improvement in 
lumen caliber [23, 24]. These changes in plaque morphology 
at tissue levels can be considered to confer clinical stabiliza-
tion regarding the triggering of acute cardiovascular events 
[23].
Conclusion
The Pro(a)LiFe-study confirmed with a prospective multi-
center design that LA can be regarded as an important thera-
peutic approach to effectively reduce Lp(a) plasma levels 
and prevent cardiovascular events in high-risk patients with 
Lp(a)-HLP. Stabilization of atherosclerotic vascular lesions 
by pulsed lipoprotein elimination could be an underlying 
mechanism of action at tissue levels.
lines the putative causal role of Lp(a) for the progressive 
course of CVD in investigated patients (Fig. 1) Analysis of 
mean annual event rates showed a significant increase for 
major adverse cardiac events (MACE) and for adverse car-
diac or vascular events (ACVE) between year –2 and year 
–1, reflecting accelerated progression of CVD [7]. Year + 1 
after commencing chronic LA was characterized by a strik-
ing reduction of MACE and ACVE rates in comparison with 
year − 1. Also, individual components of MACE, i.e., myo-
cardial infarction, percutaneous coronary intervention, and 
coronary artery bypass graft and ACVE, e.g., cerebrovascu-
lar events followed this pattern. Significant decline of mean 
event rates of MACE and ACVE continued from year + 1 
to year + 2 (Fig. 2). According to the identical observation 
periods for all patients, the mean rates directly correspond 
to differences in absolute numbers of events. In total, 142 
MACE before LA versus 31 MACE during LA could be 
translated into a number needed to treat of 3 to prevent 1 
MACE per patient per year for the first 2 prospective years.
Effects of LA on atherosclerosis development and 
plaque morphology
The immediate effect of regular LA is characterized by pulsed 
physical extracorporeal elimination of plasmatic Lp(a) with 
its load of oxidized phospholipids and subsequent endog-
enous replacement by nascent Lp(a). The resulting clinical 
benefit of LA is preventing cardiovascular events. Athero-
genesis represents a chronic process. Luminal stenosis occurs 
relatively late, when plaque growth outstrips the ability of the 
artery to compensate by expanding outward [23]. However, 
thrombotic complications occur suddenly and often without 
Fig. 2 Annual percentage change 
of mean annual cardiovascular 
events during the Pro(a)LiFe 
study. MACE major adverse 
cardiac event, i.e., cardiovascular 
death, nonfatal myocardial infarc-
tion, coronary bypass surgery, 
percutaneous coronary interven-
tion or stent. ACVE adverse car-
diac or vascular events, i.e., the 
sum of all documented cardiac 
or vascular events in arterial and 
venous vascular beds including 
MACE, cerebrovascular event, 
peripheral vascular event, venous 
thrombotic event (deep venous 
thrombosis or pulmonary embo-
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